HCV+ liver transplant: DAAs achieve 96% clearance rate in viraemic recipients

  • Kapila N & al.
  • J Clin Transl Hepatol
  • 28 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Direct-acting antivirals (DAAs) are associated with a 95.8% clearance rate among HCV+ recipients of viraemic liver transplant.

Why this matters

  • HCV+ organs have become more ubiquitous during the current opioid crisis yet remain underused; this study adds evidence for their viability.

Study design

  • Study of 24 HCV+ patients (67% male; median age, 63 years; HCV-1a, 79.2%) receiving livers from HCV+ donors; 5 (20.8%) underwent a combined liver-kidney transplant.
  • Most had HCV-1a (79.2%) and were treatment-experienced (54.2%; DAAs, 8.3%); 45.8% had hepatocellular carcinoma at transplant.
  • Median modified model for end-stage liver disease score, 19 (range, 14-35).
  • Median waitlist time, 81 (range, 4-397) days.
  • Funding: None disclosed.

Key results

  • Median time from transplant to DAA therapy, 123 (range, 10-350) days.
  • 3 patients (12.5%) transitioned to a different HCV genotype posttransplant.
  • Most received 12-24 weeks of sofosbuvir combined with ledipasvir (83.3%), velpatasvir (8.3%), or daclatasvir (4.2%); 62.5% of courses were ribavirin-free.
  • 95.8% achieved sustained virologic response at 12 weeks posttreatment (SVR12).
    • Data for 17 patients showed 100% sustained clearance at week 24.
  • Adverse events (20.8%) did not require discontinuation.
  • 2 patients (1 nonresponse, 1 relapse) were successfully retreated with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir/voxilaprevir, respectively.

Limitations

  • Retrospective design.
  • Small sample size.
  • Regimen heterogeneity.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit